We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Optibrium, Bugworks Sign Agreement for StarDrop License
Product News

Optibrium, Bugworks Sign Agreement for StarDrop License

Optibrium, Bugworks Sign Agreement for StarDrop License
Product News

Optibrium, Bugworks Sign Agreement for StarDrop License


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Optibrium, Bugworks Sign Agreement for StarDrop License"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy


Antimicrobial resistance Biopharma selects StarDrop to guide discovery of next generation of antibiotic. 


Optibrium™, a developer of software for small molecule discovery, and Bugworks Research Inc. (Bugworks), a company focused on discovering biopharmaceuticals for the treatment of critical and serious bacterial infections, recently announced the signing of a two-year agreement to license Optibrium’s StarDrop™ software.  The agreement will see deployment of StarDrop and five of its plug-in modules enabling Bugworks’ scientists at their research site in India to quickly understand structure-activity relationships, identify potential liabilities and design new compounds with the highest chance of success. 


Dr V. Balasubramanian, President R&D of Bugworks commented: “The antibiotic pipeline lacks new mechanisms against drug resistant Gram-negative bacteria. Our own in-house efforts to address this are complemented by StarDrop’s intuitive user interface and unique approach to multi-parameter optimisation and compound design.” 


Nick Foster, Optibrium’s Head of Commercial Operations, added: “We are delighted to welcome Bugworks to the family of StarDrop users. Antibiotic resistance is a growing global concern and we look forward to supporting the use of StarDrop in the discovery of new ways to combat superbugs.”


Dr Girinath Pillai, CEO at Zastra Innovations, Optibrium’s distribution partner in India, added: “We are very pleased to have been able to support Optibrium and Bugworks in establishing the license agreement. We will continue to ensure easy and fast access to StarDrop with our dedicated team for local on-call and on-site support.” 


StarDrop is a comprehensive suite of integrated software with a highly visual and user-friendly interface. It enables a seamless flow from the latest data through to predictive modelling and decision-making regarding the next round of synthesis and research, improving the speed, efficiency, and productivity of the drug discovery process. Seamlessly connecting with other informatics methods and databases, StarDrop provides user-friendly access to resources, making project management quicker and simpler. 


Advertisement